Menu
2019

RedHill Biopharma Provides Full-Year 2018 Financial Results and Operational Highlights

26 February, 2019

TEL-AVIV, Israel and RALEIGH, N.C., February 26, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today reported its full-year 2018 financial results and operational highlights.           

Key Highlights:

  • Positive top-line results from the confirmatory Phase 3 study with TALICIA® for eradication of H. pylori infection; NDA filing expected in H1/19 with potential U.S. commercial launch in Q4/19

  • Positive top-line results from a first Phase 3 study with RHB-104 for Crohn’s disease; FDA meeting planned mid-2019

  • Initiation of pivotal Phase 3 study with RHB-204 for first-line treatment of pulmonary nontuberculous mycobacteria (NTM) infections expected in H2/19

  • Strengthening of commercial management team with appointment of Rick D. Scruggs, former executive VP at Salix Pharmaceuticals, as RedHill’s chief operating officer, U.S. operations

  • Debt-free balance sheet with approximately $53 million in cash as of December 31, 2018

  • Net revenues of $8.4 million and gross margin of 66% in 2018, compared to net revenues of $4.0 million and gross margin of 47% in 20171

 

Micha Ben Chorin, RedHill’s chief financial officer, said: “We had a successful 2018 with positive data reported from our two key Phase 3 studies: the confirmatory Phase 3 study with TALICIA® for eradication of H. pylori infection and the first Phase 3 study with RHB-104 for Crohn’s disease.”

 Ben Chorin added: “We enter 2019 with a solid cash position of $53.2 million and a debt-free balance sheet. One of our potential key upcoming milestones this year is the planned filing of a U.S. NDA for TALICIA® in the first half of 2019, which is expected to support a potential commercial launch in the fourth quarter of 2019, subject to FDA approval. Additionally, we expect to meet with the FDA to discuss the development path to potential approval of RHB-104 for Crohn’s disease following the positive Phase 3 study results. We also plan to initiate a pivotal Phase 3 study with RHB-204 for potential first-line treatment of pulmonary nontuberculous mycobacteria (NTM) infections, an orphan disease with a strong unmet medical need, in the second half of 2019.”

“We continue to strengthen our commercial management team with senior industry executives and are pleased to have Rick D. Scruggs, a former senior executive at Salix Pharmaceuticals, expand his role as chief operating officer, U.S. operations to lead our growing U.S. commercial operations. For 2019, our established sales team is positioned to drive revenue growth with a lineup of four commercial products. In an effort to drive additional revenue growth and further leverage our existing U.S. commercial operations, we continue to evaluate opportunities to in-license and acquire additional U.S commercial products,” concluded Mr. Ben Chorin.

Select 2018 operational highlights:

TALICIA® (RHB-105)2 - Eradication of H. pylori Infection
Following the positive results from the confirmatory Phase 3 study with TALICIA® for eradication of H. pylori infection (ERADICATE Hp2 study), RedHill plans to submit a New Drug Application (NDA) to the Food and Drug Administration (FDA) in the first half of 2019, with eligibility for six-month priority review and potential U.S. commercial launch in the fourth quarter of 2019, subject to FDA approval.

RHB-104 - Crohn’s Disease
The first Phase 3 study with orally-administered RHB-104 for the treatment of Crohn’s disease (MAP US study) successfully met both its primary endpoint and key secondary endpoints and confirmed the broad benefit of RHB-104 as an add-on therapy to standard-of-care treatments for Crohn’s disease. RedHill continues to assess additional data from the positive study as it becomes available and plans to meet with the FDA mid-2019 to discuss the development path towards potential approval.

RHB-204 - Pulmonary Nontuberculous Mycobacteria (NTM) Infections          
A pivotal Phase 3 study with RHB-204 for the treatment of pulmonary nontuberculous mycobacteria infections is expected to be initiated in the second half of 2019, subject to completion of the ongoing supportive non-clinical program and additional input from the FDA. The study is intended to assess the efficacy and safety of RHB-204 and potentially support its approval as a first-line treatment for pulmonary NTM infections caused by Mycobacterium avium complex (MAC).

BEKINDA® (RHB-102) - Gastroenteritis and Gastritis and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
Following the successful completion of a first Phase 3 study with BEKINDA® for gastroenteritis and gastritis and guidance provided by the FDA, RedHill is currently working to design a confirmatory Phase 3 study to support a potential NDA for BEKINDA® for acute gastroenteritis and gastritis.

RedHill held a positive end-of-Phase 2/pre-Phase 3 (Type B) meeting with the FDA discussing the clinical and regulatory pathway towards potential U.S. approval of BEKINDA® for the treatment of IBS-D.  RedHill is currently finalizing the design of two pivotal Phase 3 studies with BEKINDA® for IBS-D.

YELIVA® (opaganib, ABC294640) - Cholangiocarcinoma
The ongoing Phase 2a study evaluating the activity of orally-administered YELIVA® in advanced cholangiocarcinoma (bile duct cancer) achieved its pre-specified efficacy goal for the first stage of the two-stage study design and advanced to its second stage. Enrollment of the full cohort of 39 evaluable patients is expected to be completed in the second half of 2019.

U.S. Commercial Highlights:

RedHill currently commercializes and promotes four GI-specialty products in select U.S. territories, Donnatal® (Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide)3, EnteraGam® (serum-derived bovine immunoglobulin/protein isolate SBI)4, Mytesi® (crofelemer 125 mg delayed-release tablets)5 and Esomeprazole Strontium DR Capsules 49.3 mg6.

RedHill expanded its leadership team with the appointment of Rick D. Scruggs as chief operating officer, U.S. operations. With more than 25 years of experience in the pharmaceutical industry, Rick has extensive experience in commercial operations and business development, having served as executive vice president of business development at Salix Pharmaceuticals, Inc., up to its acquisition by Valeant Pharmaceuticals International, Inc. (now Bausch Health Companies Inc.).

Full-Year 2018 Results 7

  • Net Revenues of $8.4 million for 2018, compared to $4.0 million for 20178.

  • Cost of Revenues of $2.8 million for 2018, compared to $2.1 million for 2017. 

  • Gross Profit of $5.5 million for 2018, compared to $1.9 million for 2017; with gross margin increased from 47% to 66%.
     
  • Research and Development Expenses of $24.9 million for 2018, compared to $33.0 million for 2017. The decrease was mainly due to the finalization of the Phase 3 study with RHB-104 and completion of the clinical studies with BEKINDA®.
     
  • Selling, Marketing and Business Development Expenses were $12.5 million for 2018, compared to $12.0 million for 2017.
     
  • General and Administrative Expenses were approximately $7.5 million for 2018, compared to $8.0 million for 2017.
     
  • Operating Loss of $39.3 million for 2018, compared to $52.0 million for 2017.
     
  • Net Cash Used in Operating Activities was $34.5 million for 2018, compared to $44.8 million for 2017.
     
  • Net Cash Provided by Financing Activities was $41.8 million for 2018, compared to $25.7 million for 2017. The increase was mainly due to higher gross proceeds raised in underwritten public offerings.
     
  • Cash Balance9 as of December 31, 2018, was $53.2 million, compared to $46.2 million as of December 31, 2017.
     

Conference Call and Webcast Information:

The Company will host a conference call today, February 26, 2019, at 8:30 a.m. EST to review the financial results and operational highlights.

The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, http://ir.redhillbio.com/events. Please access the Company's website at least 15 minutes ahead of the conference call to register.

Availability of RedHill’s Annual Report on Form 20-F Through its Website

RedHill’s Annual Report on Form 20-F, containing audited financial statements for the year ended December 31, 2018, as filed with the Securities and Exchange Commission on February 26, 2019, is available on its website (http://www.redhillbio.com). Shareholders may receive a hard copy of the annual report free of charge upon request.            

About RedHill Biopharma Ltd.   
RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company, primarily focused on the development and commercialization of late-stage clinical, proprietary drugs for the treatment of gastrointestinal diseases. RedHill commercializes and promotes four gastrointestinal products in the U.S.; Donnatal® - a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; EnteraGam® - a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools; Mytesi® - an anti-diarrheal drug indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy, and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg - a prescription proton pump inhibitor indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal conditions. RedHill’s key clinical-stage development programs include: (i) TALICIA® (RHB-105) for the treatment of Helicobacter pylori infection with two positive Phase 3 studies; (ii) RHB-104, with positive top-line results from a first Phase 3 study for Crohn's disease; (iii) RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (iv) BEKINDA® (RHB-102), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v) YELIVA® (ABC294640), a first-in-class SK2 selective inhibitor, targeting multiple oncology, inflammatory and gastrointestinal indications, with an ongoing Phase 2a study for cholangiocarcinoma; (vi) RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd. and (vii) RHB-107 (formerly MESUPRON), a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases.

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its therapeutic candidates; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to successfully commercialize and promote Donnatal®, EnteraGam®, Mytesi® and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; and (xiv) competition from other companies and technologies within the Company’s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on February 26, 2019. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.

 

Company contact:

Adi Frish
Senior VP Business Development & Licensing
RedHill Biopharma
+972-54-6543-112
adi@redhillbio.com

 

IR contact (U.S.):

Timothy McCarthy, CFA, MBA
Managing Director, Relationship Manager
LifeSci Advisors, LLC
+1-212-915-2564
tim@lifesciadvisors.com

 

REDHILL BIOPHARMA LTD.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

 

 

Year Ended December 31,

 

2018

2017

 

U.S. dollars in thousands

NET REVENUES

 8,360

 4,007

COST OF REVENUES

 2,837

 2,126

GROSS PROFIT

 5,523

 1,881

RESEARCH AND DEVELOPMENT EXPENSES, net

 24,862

 32,969

SELLING, MARKETING AND BUSINESS DEVELOPMENT EXPENSES

 12,486

 12,014

GENERAL AND ADMINISTRATIVE EXPENSES

 7,506

 8,025

OTHER EXPENSES

 —

 845

OPERATING LOSS

 39,331

 51,972

FINANCIAL INCOME

 678

 6,505

FINANCIAL EXPENSES

 167

 77

FINANCIAL INCOME, net

 (511)

 (6,428)

LOSS AND COMPREHENSIVE LOSS FOR THE YEAR

 38,820

 45,544

LOSS PER ORDINARY SHARE (U.S. dollars)

 

 

  Basic

  1. 17
  1. 26

  Diluted 

  1. 17
  1. 26

 

REDHILL BIOPHARMA LTD.

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

 

 

 December 31, 

 

2018

2017

 

U.S. dollars in thousands

CURRENT ASSETS:

 

 

Cash and cash equivalents

 29,005

 16,455

Bank deposits

 8,271

 13,163

Financial assets at fair value through profit or loss

 15,909

 16,587

Trade receivables

 958

 1,528

Prepaid expenses and other receivables

 1,876

 3,290

Inventory

 769

 653

 

 56,788

 51,676

NON-CURRENT ASSETS:

 

 

Bank deposits

 140

 152

Fixed assets

 163

 230

Intangible assets

 5,320

 5,285

 

 5,623

 5,667

TOTAL ASSETS

 62,411

 57,343

 

 

 

CURRENT LIABILITIES: 

 

 

Accounts payable

 3,324

 4,805

Accrued expenses and other current liabilities

 7,057

 6,025

Payable in respect of intangible asset purchase

 —

 1,000

 

 10,381

 11,830

 

 

 

NON-CURRENT LIABILITIES:

 

 

Derivative financial instruments

 344

 448

Royalty obligation

 500

 —

 

 844

 448

TOTAL LIABILITIES

 11,225

 12,278

 

 

 

EQUITY:

 

 

Ordinary shares

 767

 575

Additional paid-in capital

 219,505

 177,434

Accumulated deficit

 (169,086)

 (132,944)

TOTAL EQUITY

 51,186

 45,065

 

 

 

TOTAL LIABILITIES AND EQUITY

 62,411

 57,343

 

REDHILL BIOPHARMA LTD.

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

Year Ended December 31,

 

 2018

 2017

 2016

  U.S. dollars in thousands

OPERATING ACTIVITIES:

     

Comprehensive loss

 (38,820)

 (45,544)

 (29,370)

Adjustments in respect of income and expenses not involving cash flow:

 

 

 

Share-based compensation to employees and service providers

 2,678

 2,235

 1,679

Depreciation

 90

 81

 44

Write-off of intangible assets

 —

 845

 —

Fair value adjustments on derivative financial instruments

 (104)

 (5,687)

 (1,152)

Fair value losses (gains) on financial assets at fair value through profit or loss

 137

 127

 (67)

Revaluation of bank deposits

 35

 (123)

 (274)

Issuance costs in respect of warrants

 —

 —

 368

Exchange differences in respect of cash and cash equivalents

 103

 (367)

 (39)

 

 2,939

 (2,889)

 559

Changes in assets and liability items:

 

 

 

Decrease (increase) in trade receivables

 570

 (1,429)

99

Decrease (increase) in prepaid expenses and other receivables

 1,414

 (1,728)

612

Decrease (increase) in inventory

 (116)

 (653)

 —

Increase (decrease) in accounts payable

 (1,481)

 4,745

(60)

Increase (decrease) in accrued expenses and other current liabilities

 1,032

 2,729

(98)

 

 1,419

 3,664

 553

Net cash used in operating activities

 (34,462)

 (44,769)

 (28,258)

INVESTING ACTIVITIES:

 

 

 

Purchase of fixed assets

 (23)

 (146)

 (85)

Purchase of intangible assets

 (35)

 (1,035)

 (35)

Change in investment in current bank deposits

 4,869

 (13,000)

 36,838

Purchase of financial assets at fair value through profit or loss

 (6,976)

 (21,923)

 (12,246)

Proceeds from sale of financial assets at fair value through profit or loss

 7,517

 17,522

 —

Net cash provided by (used in) investing activities

 5,352

 (18,582)

 24,472

FINANCING ACTIVITIES:

 

 

 

Proceeds from issuance of ordinary shares, net of expenses

 41,902

 22,216

 35,754

Exercise of warrants and options into ordinary shares, net of expenses

 361

 3,437

 263

Repayment of payable in respect of intangible asset purchase

 (500)

 —

 —

Net cash provided by financing activities

 41,763

 25,653

 36,017

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

 12,653

 (37,698)

 32,231

EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS

 (103)

 367

 39

BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

 16,455

 53,786

 21,516

BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD

 29,005

 16,455

 53,786

SUPPLEMENTARY INFORMATION ON INTEREST RECEIVED IN CASH

 728

 469

 408

 

1 Promotional activities initiated mid-2017.

TALICIA® (RHB-105), BEKINDA® (RHB-102) and YELIVA® (opaganib, ABC294640) are investigational new drugs, not available for commercial distribution.

Donnatal® (Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide) is a prescription drug, classified as possibly effective as an adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. For more information, please see the prescribing information: http://www.donnatal.com/wp-content/uploads/2015/02/2015-02-18-Risk-Benefit-information-DTC-REV.-SE.pdf.

EnteraGam® (serum-derived bovine immunoglobulin/protein isolate, SBI) is a commercially-available medical food, intended for the dietary management of chronic diarrhea and loose stools due to specific intestinal disorders, which must be administered under medical supervision.

Mytesi® (crofelemer 125 mg delayed-release tablets) is a first-in-class anti-secretory prescription drug approved by the U.S. FDA for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on anti-retroviral therapy. For more information, see the prescribing information:              http://mytesi.com/assets/mytesi_package_insert_june_2016.pdf.

Esomeprazole Strontium Delayed-Release (DR) Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor, indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal conditions. For more information, please see the prescribing information:        https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=53240ab5-98e7-4050-b640-e09c1271899a&type=display

All financial highlights are approximate and are rounded to the nearest hundreds of thousands.

Promotional activities initiated mid-2017.

Including cash and short-term investments (bank deposits and financial assets at fair value).

Related Documents
Download file636.3 Kb